Monitor for preclinical data readout expected by early 2027. The collaboration is a non-dilutive validation but does not change the company's cash runway or near-term fundamentals. No immediate catalyst for the stock.
Price Chart
Executive Summary
Kairos Pharma entered into an Investigator Initiated Research (IIR) agreement with Bayer, under which Bayer will supply XOFIGO (radium-223) for a preclinical study combining it with Kairos' lead antibody ENV-105 (carotuximab) in models of prostate cancer bone metastasis. The press release highlights a $570M–$1.3B addressable market and prior Phase 2 data showing an 86% clinical benefit rate, but no financial terms (upfront, milestones, or royalties) were disclosed. The collaboration is early-stage and non-dilutive, providing validation but no near-term revenue.
Key Financial Metrics
Key Facts
- Bayer will supply XOFIGO (radium-223 dichloride) for a preclinical study combining it with ENV-105 (carotuximab) in prostate cancer bone metastasis models.
- Kairos is solely responsible for initiating, managing, and financing the study; Bayer has no financial obligation beyond drug supply.
- The press release references a $570M–$1.3B addressable global market and Phase 2 data showing 86% clinical benefit rate in resistant mCRPC.
- No upfront payment, milestone payments, or royalties were disclosed in the agreement.
- Study timeline: experiments start June 15, 2026, end Dec 20, 2026, report due Jan 10, 2027.
Financial Impact
No financial terms disclosed; Kairos bears all study costs. The collaboration provides drug supply only.
Risk Factors
- Preclinical study may not yield positive results; failure would not constitute a breach under the agreement.
- Bayer can terminate the agreement at any time with one month's notice without cause.
- Kairos has a $7M market cap and limited cash; the company must finance the study itself.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-034185 |
| Exhibit: ex99-1.htm | 0001493152-26-034185 |
| Document: form8-k.htm | 0001493152-26-034185 |
| Document: 0001493152-26-034185-index-headers.html | 0001493152-26-034185 |
| Document: 0001493152-26-034185-index.html | 0001493152-26-034185 |
| Document: 0001493152-26-034185.txt | 0001493152-26-034185 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $1.15 $0.8287 | ▼ −27.94% | ▼ −27.80% | $0.5251 (−54.34%) |
Jul 22, 2026 13w ago | 8-K | $0.3127 $0.2990 | ▼ −4.38% | ▼ −1.98% | $0.5251 (+67.92%) |
Jul 15, 2026 14w ago | 8-K | $0.3180 $0.3127 | ▼ −1.67% | ▼ −0.69% | $0.5251 (+65.13%) |
Jun 4, 2026 20w ago | 8-K | $0.4660 $0.4580 | ▼ −1.72% | ▲ +0.84% | $0.5251 (+12.68%) |
May 26, 2026 21w ago | DEFA14A | $0.5170 $0.4620 | ▼ −10.64% | ▼ −11.11% | $0.5251 (+1.57%) |
Feb 26, 2026 34w ago | 8-K | $0.5520 $0.6560 | ▲ +18.84% | ▲ +19.97% | $0.5251 (−4.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers